eTable 1. List of antibodies (A) and reagents for flow cytometry analysis (B)

A

Antibodies	Clone and Cat#	From
CD3 PE-Cy7	Clone SK7; Cat# 341111	BD
CD3 PE		
CD4 BV711	Clone SK3; Cat# 63028	BD
CD8 APC-H7	Clone SK1; Cat# 41400	BD
TNFα FITC	Clone MAb11; Cat# 552889	BD
IL2 PerCP-Cy5.5	Clone MQ1-17H12; Cat# 560708	BD
IFNγ BV421	Clone B27; Cat# 562988	BD
Fixable Viability stain 700 APC-R700	Cat#564997	BD

B

| Reagents	Cat#	From
Brilliant stain Buffer	563794	BD
Cytofix/Cytoperm solution kit	554714	BD

eTable 2. Health status of the health care workers enrolled.

| Health Care Workers Status			Total (N=78)	Frequency (%)
Disease status	Healthy		64	82.0
	Endocrine And Metabolic Diseases	Hypothyroidism	6	9.0
		Diabetes Mellitus	1	
	History of Allergy		3	4.0
	Cardiovascular Diseases	Arrhythmia	1	2.5
		Hypertension	1	
	NA		2	2.5
Corticosteroids	Yes*		3	4
	No		73	93.5
	NA		2	2.5

Footnotes: NA: information not available; ***Corticosteroids were taken by the HCWs reporting allergic diseases. Dosage was not reported.

eFigure 1

eFigure 1. Anti-N-IgG levels of MS vaccinated patients. Evaluation of anti-N-IgG levels in MS vaccinated patients stratified according to drug treatment in four groups: ocrelizumab (n=25), fingolimod (n=35), cladribine (n=20) and IFN-β (n=28). SARS-CoV-2 specific anti-N Abs were quantified in plasma or sera samples. Anti-N-IgG are expressed as Arbitrary Units (AU)/mL and values $\geq$ 1.4 are considered positive. Each black dot represents one sample. Dashed line identifies the cut-off of 1.4 AU/mL. The red horizontal lines represent the median; statistical analysis was performed using the Mann-Whitney test, and p value was considered significant if $\leq$0.0125. Footnotes: N, Nucleocapsid; Abs, antibodies.

eFigure 2

eFigure 2. Flow cytometry gating strategy. T-cell subpopulations were gated as shown according to the expression of surface markers.